NCT07520565 A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
| NCT ID | NCT07520565 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Biocells (Beijing) Biotech Co.,Ltd |
| Condition | AIS |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,112 participants |
| Start Date | 2026-01-19 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,112 participants in total. It began in 2026-01-19 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke
Eligibility Criteria
Inclusion Criteria: 1. Age18\~85 (including 18 and 85 years)，no gender limitation; 2. Subjects diagnosed with acute ischaemic stroke according to the Chinese Guidelines for Clinical Management of Cerebrovascular Disease (2nd edition); 3. 8 ≤ NIHSS score ≤ 25 before randomisation，and the sum of the score of the 5th upper limb and the 6th lower limb was ≥ 2 ; 4. Within 3h of stroke onset and expected to be able to start receiving the investigational product within 3 h of stroke onset (note: stroke onset time was calculated from the onset time of stroke symptoms; if stroke onset occurs during sleep, the stroke onset time should be taken as the latest normal appearance time); 5. First stroke onset, or have a history of stroke but good prognosis (mRS score ≤1); 6. Subjects who are able to understand and comply with the study procedures, and who agree to sign the study informed consent form in writing to indicate that they are willing to participate in the trial (the informed consent form can be signed by subjects or their legal representatives). Exclusion Criteria: 1. Imaging confirmed intracranial hemorrhagic disease (hemorrhagic stroke, epidural hematoma, intracranial hematoma, subarachnoid hemorrhage, ventricular hemorrhage, traumatic cerebral hemorrhage, etc.); 2. Severe disturbance of consciousness: NIHSS 1a score ≥2 points; 3. After aggressive antihypertensive therapy, hypertension still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥110 mmHg; 4. Severe hyperglycemia/hypoglycemia: blood glucose≥400 mg/dL (22.2 mmol/L), or ≤50 mg/dL (2.8 mmol/L); 5. Heart rate \< 50 beats /min or heart rate \> 120 beats /min; Heart failure, unstable angina pectoris, acute myocardial infarction, and severe arrhythmias within the previous 6 months; 6. Previously diagnosed severe hepatic and renal dysfunction and determined by the investigators as affect the subjects; 7. Patients who have suffered from malignant tumors or are undergoing anti-tumor treatment within the past 5 years; 8. Patients who have been treated with neuroprotective agents after current stoke onset; 9. Have a epilepsy history or have epilepsy symptoms after current stoke onset; 10. Combined with other mental illnesses, resulting in inability or unwillingness to cooperate; 11. Combined with claudication, osteoarthropathy, etc., resulting in limb movement dysfunction, which is determined by investigators to affect neurological function test; 12. History of severe head trauma or stroke within 3 months before screening; 13. History of severe food or drug allergy, or known allergy to the investigational drug and its excipients; 14. Expected survival period is less than 3 months; 15. Pregnant, planning pregnancy or breastfeeding patients; 16. Suspected or confirmed history of alcohol or drug abuse; 17. Participated in other drug or device clinical trial within the 1 months prior to screening or are participating in a other clinical trial; 18. Other conditions, and the investigator assessed that participation in the study might increase the patient's risk or that participation in the study was deemed inappropriate by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07520565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying AIS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07520565 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,112 participants.
Is NCT07520565 currently recruiting?
Yes, NCT07520565 is actively recruiting participants. Contact the research team at zhangxiaoming@biocells.cn for enrollment information.
Where is the NCT07520565 trial being conducted?
This trial is being conducted at Hengshui, China, Daqing, China, Nanyang, China, Meihekou, China and 5 additional locations.
Who is sponsoring the NCT07520565 clinical trial?
NCT07520565 is sponsored by Biocells (Beijing) Biotech Co.,Ltd. The trial plans to enroll 1,112 participants.